Towards improved cancer therapy using subcutaneously administered hemopoietic colony stimulating factors.
Morstyn
G
G
Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Victoria, Australia.
Sheridan
W
W
Lieschke
G
G
Cebon
J
J
Layton
J
J
Fox
R
R
D000970:Antineoplastic Agents / Q000009:adverse effects*; D016190:Carboplatin / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005047:Etoposide / Q000009:adverse effects; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D007279:Injections, Subcutaneous; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy*
D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D016190:Carboplatin